One in 5 teenage girls suffer severe dysmenorrhea, and approximately 1 in 4 women have a pelvic pain condition. This represents a major economic and social unmet need, which is replicated throughout the world.
Increasing evidence suggests that pain in women may act via different mechanisms than pain in men. Pain in women has been under-researched, providing an opportunity for new developments and world-first technologies.
Alyra Biotech Pty Ltd is an 100% Australian, privately owned, startup company specialising in the development and commercialization of novel technologies to manage pelvic pain in women.
Alyra Biotech lodged it’s first patent application in 2018: a novel, non-opioid, concept in pelvic pain prevention and management, suited to women throughout the world.
Contact Alyra Biotech: alyra@drsusanevans.com.au